A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remissionNorbert Vey, Daniel Olive, Thomas Prébet et al.|Blood|2012Cited by 269
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyMichael B. Lilly, Giovanni Martinelli, Oliver G. Ottmann et al.|American Journal of Hematology|2009Cited by 98